IL37 and atherosclerosis: Moreover, a recent study showed that recombinant IL-37 treatment reduced atherosclerosis development and improved plaque composition (i.e., reduced macrophage content and increased collagen and smooth muscle cell content) under low inflammatory conditions [17].